DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:Jefferies London Global
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) –– Company raises full year 2026 total revenue guidance –– Ziihera® launched in HER2+ 1L mGEA –– Xywav® revenues grew 12% YoY with
Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors onlyDUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc
Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 monthsMature HERIZON-GEA-01 results show Ziihera plus chemotherapy
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial
TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced the appointment of
Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsyTransaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment
DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:Wells Fargo 21st Annual
HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEALonger follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032
DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEACompany to
Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsiesTransaction includes $820 million
– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) –– Company raises 2026 revenue guidance –– Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FDA approval ––
DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial
